CL2021003435A1 - Fragmentos de unión a antígeno egfr y composiciones que los comprenden. - Google Patents
Fragmentos de unión a antígeno egfr y composiciones que los comprenden.Info
- Publication number
- CL2021003435A1 CL2021003435A1 CL2021003435A CL2021003435A CL2021003435A1 CL 2021003435 A1 CL2021003435 A1 CL 2021003435A1 CL 2021003435 A CL2021003435 A CL 2021003435A CL 2021003435 A CL2021003435 A CL 2021003435A CL 2021003435 A1 CL2021003435 A1 CL 2021003435A1
- Authority
- CL
- Chile
- Prior art keywords
- compositions
- binding fragments
- egfr
- egfr antigen
- antigen
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 108060006698 EGF receptor Proteins 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente descripción se refiere a unidades de unión a antígeno que se unen específicamente a EGFR o epítopos de este. Algunas modalidades incluyen constructos anti-EGFR/anti-CD3 biespecíficos con expresión y/o estabilidad mejoradas. También se describen métodos relacionados.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962866749P | 2019-06-26 | 2019-06-26 | |
US202063043486P | 2020-06-24 | 2020-06-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021003435A1 true CL2021003435A1 (es) | 2022-09-02 |
Family
ID=74060335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021003435A CL2021003435A1 (es) | 2019-06-26 | 2021-12-21 | Fragmentos de unión a antígeno egfr y composiciones que los comprenden. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230312729A1 (es) |
EP (1) | EP3990499A4 (es) |
JP (1) | JP2022538222A (es) |
KR (1) | KR20220038356A (es) |
CN (1) | CN114729056A (es) |
AU (1) | AU2020303586A1 (es) |
CA (1) | CA3143522A1 (es) |
CL (1) | CL2021003435A1 (es) |
CO (1) | CO2022000404A2 (es) |
IL (1) | IL289100A (es) |
MX (1) | MX2021015882A (es) |
WO (1) | WO2020264208A1 (es) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20110774A1 (es) * | 2008-08-18 | 2011-10-13 | Amgen Fremont Inc | Anticuerpos para ccr2 |
AU2014206217B2 (en) * | 2009-02-03 | 2015-09-17 | Amunix Pharmaceuticals, Inc. | Extended recombinant polypeptides and compositions comprising same |
EP2729488A4 (en) * | 2011-07-06 | 2015-01-14 | Medimmune Llc | PROCESS FOR PREPARING MULTIMANT POLYPEPTIDES |
EP2768858B1 (en) * | 2011-10-18 | 2018-08-01 | Emory University | Antibodies directed against influenza |
CR20160425A (es) * | 2014-03-14 | 2017-05-26 | Novartis Ag | Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas |
TWI744247B (zh) * | 2015-08-28 | 2021-11-01 | 美商亞穆尼克斯製藥公司 | 嵌合多肽組合體以及其製備及使用方法 |
BR112018007703A2 (pt) * | 2015-10-30 | 2018-11-06 | Genentech Inc | anticorpos, ácido nucleico isolado, métodos de produção de um anticorpo e de tratamento de um distúrbio, composição farmacêutica, terapia de combinação e uso do anticorpo |
US11059908B2 (en) * | 2016-09-29 | 2021-07-13 | Amgen Inc. | Low-viscosity antigen binding proteins and methods of making them |
CN106632681B (zh) * | 2016-10-11 | 2017-11-14 | 北京东方百泰生物科技有限公司 | 抗egfr和抗cd3双特异抗体及其应用 |
EP3574018A4 (en) * | 2017-01-27 | 2020-10-07 | Silverback Therapeutics, Inc. | CONJUGATES TARGETING TUMORS AND THEIR METHODS OF USE |
WO2019090355A1 (en) * | 2017-11-06 | 2019-05-09 | Children's National Medical Center | Cells expressing antibodies and methods of treatment using the same |
-
2020
- 2020-06-25 AU AU2020303586A patent/AU2020303586A1/en not_active Abandoned
- 2020-06-25 CN CN202080061211.XA patent/CN114729056A/zh active Pending
- 2020-06-25 JP JP2021576274A patent/JP2022538222A/ja active Pending
- 2020-06-25 WO PCT/US2020/039682 patent/WO2020264208A1/en active Application Filing
- 2020-06-25 MX MX2021015882A patent/MX2021015882A/es unknown
- 2020-06-25 US US17/621,978 patent/US20230312729A1/en active Pending
- 2020-06-25 CA CA3143522A patent/CA3143522A1/en active Pending
- 2020-06-25 EP EP20833213.0A patent/EP3990499A4/en active Pending
- 2020-06-25 KR KR1020227002556A patent/KR20220038356A/ko unknown
-
2021
- 2021-12-19 IL IL289100A patent/IL289100A/en unknown
- 2021-12-21 CL CL2021003435A patent/CL2021003435A1/es unknown
-
2022
- 2022-01-19 CO CONC2022/0000404A patent/CO2022000404A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022538222A (ja) | 2022-09-01 |
MX2021015882A (es) | 2022-04-18 |
EP3990499A1 (en) | 2022-05-04 |
KR20220038356A (ko) | 2022-03-28 |
AU2020303586A1 (en) | 2022-01-20 |
IL289100A (en) | 2022-02-01 |
CA3143522A1 (en) | 2020-12-30 |
US20230312729A1 (en) | 2023-10-05 |
WO2020264208A1 (en) | 2020-12-30 |
CN114729056A (zh) | 2022-07-08 |
CO2022000404A2 (es) | 2022-05-31 |
EP3990499A4 (en) | 2023-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124384T1 (el) | Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3 | |
CY1124472T1 (el) | Κατασκευασματα διειδικων αντισωματων που δεσμευουν dll3 και cd3 | |
ECSP20024555A (es) | Anticuerpos especificos para cd47 y pd-l1 | |
CL2020003416A1 (es) | Constructos de anticuerpo biespecificos que se unen a mesotelina y cd3 (divisional sol. 201800268) | |
ECSP17081420A (es) | Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales | |
CU20200090A7 (es) | Anticuerpos frente a entpd2 y terapias de combinación | |
CO2019012210A2 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos | |
EA201690447A1 (ru) | БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬСЯ С gpA33 И CD3, И ИХ ПРИМЕНЕНИЯ | |
MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
UY37030A (es) | Anticuerpos dirigidos a cd32b y métodos de uso de los mismos | |
CU24533B1 (es) | Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos | |
ECSP22005986A (es) | Fragmentos de unión al antígeno cd3 y composiciones que comprenden los mismos | |
EA201791270A1 (ru) | Модифицированные april-связывающие антитела | |
CO2020012360A2 (es) | Anticuerpos multiespecíficos y utilización de los mismos | |
AR105267A1 (es) | Anticuerpos de unión a tau | |
BR112022009723A2 (pt) | Anticorpos específicos para cd47, pd-l1, e usos dos mesmos | |
UY37683A (es) | Anticuerpo monoclonal anti-pd-l1 monoclonal | |
CO2020014343A2 (es) | Anticuerpos específicos para cd3 y sus usos | |
UY37598A (es) | Anticuerpos miméticos de fgf21 y usos de los mismos | |
MD3365367T2 (ro) | Anticorpi monoclonali împotriva ploşniţelor de pat și procedee de obţinere și utilizare a acestora | |
CO2022000404A2 (es) | Fragmentos de unión a antígeno egfr y composiciones que los comprenden | |
EA202092595A1 (ru) | Антитела к siglec-7 и способы их применения | |
BR112021026060A2 (pt) | Fragmentos de ligação ao antígeno de egfr e composições compreendendo os mesmos | |
AR107083A1 (es) | Anticuerpos dirigidos a cd32b y métodos de uso de los mismos | |
UY37915A (es) | Anticuerpos específicos para cd47 y pd-l1 |